Exagen Inc. XGN

XGN Company Overview

Exagen Inc. is a U.S.-based diagnostics company focused on autoimmune disease testing, with a primary emphasis on rheumatology and related chronic autoimmune conditions. The company develops, commercializes, and operates laboratory testing services intended to support earlier and more accurate diagnosis, prognosis, and disease management for conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and other connective tissue diseases. Exagen operates within the molecular diagnostics, clinical laboratory services, and precision medicine industries, with revenue primarily generated through reimbursement for proprietary diagnostic testing services provided to physicians, healthcare systems, and payors.

The company’s principal commercial offering is the AVISE® testing portfolio, including AVISE® CTD, which combines biomarker analysis, cell-bound complement activation products, and algorithmic interpretation intended to improve autoimmune disease differentiation. Exagen was founded in 2002 and evolved from a specialty diagnostics enterprise into a focused autoimmune testing company through internal assay development, clinical validation programs, and commercialization efforts targeting rheumatologists across the United States. Its strategic positioning is tied to proprietary biomarker technology, established rheumatology relationships, and a concentrated focus on autoimmune diagnostics rather than broader general laboratory services.